A comparison of two long-acting β-agonists, oral bambuterol and inhaled salmeterol, in the treatment of moderate to severe asthmatic patients with nocturnal symptoms

Respiratory Medicine

Volumn 93, Issue 1, 1999, Pages 33-38

  Wallaert, B ^a   Brun, P ^b   Ostinelli, J ^c   Murciano, D ^d   Champel, F ^e   Blaive, B ^f   Montane F ^g   Godard, P ^h   Blanchon, F ^g   Brambilla, C ^g   Caillaud, D ^g   Cordier, J F ^g   Delaval, P ^g   Delhoume, Y ^g   Dennewald, G ^g   Dewitte, J D ^g   Didier, A ^g   Fournier, E ^g   Herer, B ^g   Lavandier, M ^g   Proust, A ^g   Rochemaure, J ^g   Viau, F ^g   more..

^a LILLE UNIVERSITY HOSPITAL   (France)

^b HÔPITAL LOUIS MOURIER   (France)

^c Laboratoires Astra France   (France)

^d BEAUJON HOSPITAL   (France)

^e Centre Médical Pneumologie   (France)

^f PASTEUR HOSPITAL   (France)

^g Hôpital Arnaud de Villeneuve ^*

^h HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BAMBUTEROL; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; SALMETEROL;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INSOMNIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; NIGHT; ORAL DRUG ADMINISTRATION; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TACHYCARDIA; TREMOR;

EID: 13044279481     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(99)90074-4     Document Type: Article

References (13)

1. National Heart, Lung and Blood Institute. International Consensus Report on Diagnosis and Treatment of Asthma. National Institutes of Health, Bethesda, Maryland 20892 Publication No. 92-3091, March 1992. Eur Respir J 1992; 5: 601:641.
2. Liard R, Zureik M, Aubier M, Korobaeff M, Henry C, Neukirch F. Misuse of pressurized metered dose inhalers by asthmatic patients treated in French private practice. Rev Epidem Santé Publ 1995; 43: 242-249.
3. Olsson OAT, Svensson LA. New lipophilic terbutaline ester prodrugs with long effect duration. Pharm Res 1984; 1: 19-23.
4. Sitar DS, Aoki FY, Warren CP, et al. A placebo controlled dose-finding study with bambuterol in elderly patients with asthma. Chest 1993; 103: 771-776.
5. Nyberg L. Pharmacokinetic properties of bambuterol in solution and tablet basis for once-daily dosage in asthma. Acta Pharmacol Toxicol 1986; 59 (Suppl. 5): 229 (abstract).
6. D'Alonzo GE, Smolensky MH, Feldman S, Gnosspelius Y, Karlsson K. Bambuterol in the treatment of asthma. A placebo-controlled comparison of once-daily morning vs evening administration. Chest 1995; 107: 406-412.
7. Gunn SD, Ayres JG, McConchie SM. Comparison of the efficacy, tolerability and patient acceptability of once-daily bambuterol tablets against twice-daily controlled release salbutamol in nocturnal asthma. Eur J Clin Pharmacol 1995; 48: 23-28.
8. Larsen K, Schmekel B. Tremor in healthy volunteers after bambuterol and terbutaline CR-tablets. Eur J Clin Pharmacol 1993; 45: 303-305.
9. Petrie GR, Chookang JY, Hassan WU, et al. Bambuterol: effective in nocturnal asthma. Respir Med 1993; 87: 581-585.
10. 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax 1988; 43: 674-678.
11. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481-1488.
12. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219-224.
13. 2-agonist bambuterol in asthmatic patients. Eur Respir J 1995; 8: 34-39.